echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Preliminary clinical results of HER3-targeted ADC for non-small cell lung cancer are positive

    Preliminary clinical results of HER3-targeted ADC for non-small cell lung cancer are positive

    • Last Update: 2021-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 4, 2021, Daiichi Sankyo announced that its research antibody conjugate (ADC) patritumab deruxtecan, targeting HER3, is in the treatment of non-small cell lung cancer (NSCLC) with drug-resistant EGFR mutations.


    Patritumab deruxtecan is one of the three main DXd ADCs produced by Daiichi Sankyo.


    The test results showed that among 57 enrolled patients who received patritumab deruxtecan (5.


    ▲Patritumab deruxtecan preliminary clinical trial research results (picture source: reference [1])

    Lung cancer is one of the most common cancers and the leading cause of cancer deaths worldwide


    Note: The original text has been deleted

    Reference materials:

    [1] Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.